In the News
‘Better things are coming’: Brepocitinib improves scarring alopecia biomarkers, severity
March 15, 2024: Findings presented at American Academy of Dermatology
Brepocitinib induced clinical improvement in patients with cicatricial alopecia and attenuated scalp inflammatory biomarkers, according to a presentation at the American Academy of Dermatology Annual Meeting… continue reading
Clinique, Icahn School of Medicine at Mount Sinai Join Forces to Establish the Mount Sinai-Clinique Healthy Skin Dermatology Center
February 2, 2024: New partnership announced
Clinique has made a philanthropic commitment of $5 million over seven years for the advancement and evolution of allergy science through the partnership and founding of the Mount Sinai-Clinique… continue reading
Tape strips may identify hidradenitis suppurativa in lesional, nonlesional skin
December 08, 2023: Insight into a recently published paper in the Journal of the American of Dermatology.
Tape strips show promise as a minimally invasive way to identify hidradenitis suppurativa and create individualized treatment plans for patients with this disease, according to a study… continue reading
Majority of Atopic Dermatitis Patients Maintained Clear Skin with Lebrikizumab Over 2 Years
October 20, 2023: These findings, presented at the Fall Clinical Dermatology conference, resulted from the ADjoin long-term extension study.
Individuals with moderate-to-severe atopic dermatitis (AD) that maintain monthly dosing of lebrikizumab therapy for up to 2 years may sustain pruritus relief, clearance of skin, and AD severity, according to new findings presented at the Fall Clinical Dermatology Conference in Las Vegas… continue reading
Continuous Upadacitinib Treatment of Atopic Dermatitis Suggested to Ensure Maintenance of Skin Clearance
August 21, 2023: In this latest research, the investigators noted that upadacitinib therapy may also be utilized as a treatment option for atopic dermatitis patients who experience a flare.
Discontinuation of upadacitinib followed by reintroduction for adults with moderate-to-severe atopic dermatitis (AD) leads to diminished results followed by rapid recovery of both skin and itch responses, according to recent findings, indicating continuous upadacitinib treatment’s potential… continue reading
Atopic Dermatitis: Mount Sinai Study Finds Lebrikizumab May Allow Longer Interbals Between Treatments
July 18, 2023: Posted at 21:22h in Author Interviews, Dermatology, Immunotherapy
MedicalResearch.com: What is the background for this study?
Response: The idea to test how spacing out treatment or even stopping it affects treatment responses once patients are well controlled. Lebrikizumab it is a potent biologic agent with a relatively long-lasting effect… continue reading
Dr Emma Guttman-Yassky: Strong Real-World Results of Biologics, JAK Inhibitors in AD
July 16, 2023: Some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice compared with clinical trials, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai.
It’s not uncommon for real-world results and outcomes for a treatment to be worse than those seen in clinical trials, which are more tightly controlled and have strict inclusion criteria. However, some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have… continue reading
Where to Find Support for Alopecia Areata
May 19, 2023: Feeling alone in your hair-loss experience? These support groups and advocacy organizations have your back.
When you’re managing a chronic autoimmune condition like alopecia areata, it really helps to have a team in your corner. Ideally you’ve already found a trusted dermatologist to help manage the medical side of the condition (including finding the right treatment), but finding support is… continue reading
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
21–27 January 2023: The Lancet Volume 401, Issue 10372, Pages 204-214
OX40 is crucial for T-cell differentiation and memory induction. The anti-OX40 antibody, rocatinlimab inhibits the OX40 pathway. We evaluated the efficacy and safety of rocatinlimab in adults with moderate-to-severe atopic dermatitis… continue reading